Directory

Discover detailed profiles of PoC companies.

CellNBetter, Inc.

One-Stop Multi-Organ Automated Culture System

Specialization

Organ-on-a-Chip
Automated Cell Culture
Multi-Organ Culture System

Keywords

LOCAT
Multi-Organ Culture
Automated Drug Testing

CellNBetter develops LOCAT™, a one-stop automated culture system for multi-organ cell models and drug testing.
LOCAT™ automates multi-organ and tissue culture, drug injection, media circulation, and scheduled sampling.
The platform supports long-term organ culture for more than 90 days and enables precise drug efficacy and toxicity testing.
It is designed for biomedical research, personalized drug screening, rare disease modeling, and complex organ interaction studies.

(1) Owned Technology

(2) Applied Products

LOCAT™-W
- Ready-to-use 24-well bioink-loaded cell co-culture sample kit.
- Supports simultaneous multi-organ cell culture.
- Designed for long shelf life and mass production.
LOCAT™-S
- Automated injection, culture, and sampling equipment.
- Circulates culture media over extended periods.
- Each of four independent channels can culture up to six tissue samples.
LOCAT™ Module
- Fluidic full connection set for culture system operation.
LOCAT™ Photocrosslinking Systems
- Visible light and UV-based systems for well sample preparation.

(1) Problem Definition / Development Background

Existing cell culture and drug testing processes often depend on manual work, causing variability and low reproducibility.
Conventional single-organ models have limitations in analyzing complex inter-organ interactions.
Long-term drug response studies require stable media circulation, repeated sampling, and controlled culture conditions.
Personalized medicine and rare disease research need flexible platforms that can handle patient-derived cells and multi-organ disease models.

(2) Value Proposition / Solution

LOCAT™ provides an automated platform for multi-organ culture and drug testing.
The system reduces human error and improves reproducibility through controlled automation.
It enables long-term monitoring of cell responses, drug metabolites, toxicity, and functional indicators.
LOCAT™ helps researchers build complex organ-axis models and conduct high-throughput, customized experiments.

Long-Term Culture: Supports reliable testing for more than 90 days.
Automated Workflow: Automates drug injection, media circulation, culture, and sampling.
Multi-Organ Modeling: Enables inter-organ interaction studies such as gut–liver–brain and gut–kidney–bone axes.
High-Throughput Testing: Supports automated cultivation of multiple cells or tissues in a 24-well format.
Cost Efficiency: LOCAT™-S can save approximately USD 150K–190K in labor costs over five years.
Customizable Research Models: Supports organ-specific, disease-specific, and patient-derived cell testing.

Developed LOCAT™-W ready-to-use sample kit and LOCAT™-S automated culture equipment.
Built a technology portfolio covering culture plates, multi-organ culture equipment, and AI analysis platforms.
Holds patents related to 3D cell culture containers, multi-organ culture systems, drug screening, and image analysis.
Published related research in journals including Lab on a Chip, Biofabrication, and Bioengineering & Translational Medicine.
Product options include collagen, liver ECM, bone ECM, kidney ECM, brain ECM, and intestine ECM-based sample kits.

(1) PoC Progress

LOCAT™ is presented as a validated research platform for automated multi-organ culture and long-term drug testing.

(2) Global Expansion

CellNBetter can target global life science research institutions, pharmaceutical companies, CROs, and precision medicine labs.
The LOCAT™ platform is applicable to drug efficacy and toxicity testing, disease modeling, personalized drug screening, and rare genetic disease research.
The company can expand through partnerships in organ-on-a-chip, automated lab systems, and AI-based drug evaluation markets.